Investing.com - Aslan Pharma ADR reported on Friday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.16 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.14 on revenue of $0.00.
Aslan Pharma ADR shares are down 21.7% from the beginning of the year, still down 77.40% from its 52 week high of $3.88 set on March 26, 2021. They are under-performing the Nasdaq which is down 10.23% from the start of the year.
Aslan Pharma ADR shares lost 4.58% in intra-day trade following the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings missed by Merck ADR on March 3, who reported EPS of $0.4558 on revenue of $5.77B, compared to forecasts EPS of $0.4818 on revenue of $5.88B.
Moderna had beat expectations on February 24 with fourth quarter EPS of $11.29 on revenue of $7.21B, compared to forecast for EPS of $9.96 on revenue of $6.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar